GlobeNewsWire
22 Jul 2026, 10:50 UTC · 8w ago
Verdict
Headline takes no side. We score PHVS +0.60 across three claims — strongly bullish.
+0.60strongly bullish
More positive than 71% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Pharvaris (PHVS) is developing novel, oral bradykinin B2 receptor antagonists for hereditary and acquired angioedema.
So whatThe development of oral alternatives to injectables for these conditions represents a potential significant shift in standard of care and market share.
More positive than 76% of claims this week
A newly published review in Clinical Reviews in Allergy & Immunology validates B2 receptor antagonism as a therapeutic strategy for bradykinin-mediated diseases.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 49% of claims this week
Research suggests bradykinin B2 receptor antagonism may be applicable to a broader range of conditions, including asthma, chronic cough, and allergic rhinitis.
More positive than 40% of claims this week
Which stocks this story touches
More positive than 71% of ticker scores this week
The company is promoting the publication of a comprehensive review supporting the therapeutic target of its lead drug candidates.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
13h ago
+4.6%
Price agrees with the score
$36.02 vs $34.45 close before publication (Jul 21) · not market-adjusted
PHVS chart →